Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study-Reference-Cited by-同舟云学术

Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study

Published:2022-12-14 Issue:2 Volume:46 Page:195-208
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Layton J. Bradley^ORCID,Forns Joan^ORCID,McQuay Lisa J.^ORCID,Danysh Heather E.^ORCID,Dempsey Colleen,Anthony Mary S.^ORCID,Turner Mary Ellen

Funder

ACADIA Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-022-01260-6.pdf

Reference43 articles.

1. Kianirad Y, Simuni T. Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis. Expert Rev Clin Pharmacol. 2017;10(11):1161–8. https://doi.org/10.1080/17512433.2017.1369405.

2. Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001. https://doi.org/10.1001/archneurol.2010.166.

3. Mantri S, Klawson E, Albert S, Rapoport R, Precht C, Glancey S, et al. The experience of care partners of patients with Parkinson’s disease psychosis. PLoS ONE. 2021;16(3): e0248968. https://doi.org/10.1371/journal.pone.0248968.

4. Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, et al. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS ONE. 2021;16(1): e0246121. https://doi.org/10.1371/journal.pone.0246121.

5. Simonet C, Tolosa E, Camara A, Valldeoriola F. Emergencies and critical issues in Parkinson’s disease. Pract Neurol. 2020;20(1):15–25. https://doi.org/10.1136/practneurol-2018-002075.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antipsychotics Use in the Elderly;Advances in Psychiatry and Behavioral Health;2024-09

2. Dual 5-HT_2A and 5-HT_2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis;Journal of Medicinal Chemistry;2024-08-13

3. Adverse effects associated with antipsychotic use in older adults;Expert Opinion on Drug Safety;2024-08-12

4. Pimavanserin’s Safety Profile: Insights from a Phase 3b Clinical Trial;Journal of Alzheimer's Disease;2024-06-11

5. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis;CNS Drugs;2024-04-08